Munster PN - Search Results

1

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: munster pn. Clin Cancer Res. 2005 Dec 1;11(23):8467-75. doi: 10.1158/1078-0432.CCR-05-1073. Clin Cancer Res. 2005. PMID: 16322310

2

Purification and characterization of a novel 35-kDa protein from transformed cardiomyocytes.

Chandrasekhar S, Münster PN, Henzel WA, Daud AI. Chandrasekhar S, et al. Among authors: munster pn. Cell Biol Int. 1999;23(4):299-306. doi: 10.1006/cbir.1998.0328. Cell Biol Int. 1999. PMID: 10600238

3

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Münster PN, Basso A, Solit D, Norton L, Rosen N. Münster PN, et al. Clin Cancer Res. 2001 Aug;7(8):2228-36. Clin Cancer Res. 2001. PMID: 11489796

4

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. Munster PN, et al. Cancer Res. 2001 Dec 1;61(23):8492-7. Cancer Res. 2001. PMID: 11731433

5

Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

Münster PN, Marchion DC, Basso AD, Rosen N. Münster PN, et al. Cancer Res. 2002 Jun 1;62(11):3132-7. Cancer Res. 2002. PMID: 12036925

6

New drugs in gynecologic cancer.

Daud A, Munster P, Munster P, Spriggs DR. Daud A, et al. Curr Treat Options Oncol. 2001 Apr;2(2):119-28. doi: 10.1007/s11864-001-0054-0. Curr Treat Options Oncol. 2001. PMID: 12057130 Review.

7

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: munster pn. J Cell Biochem. 2004 May 15;92(2):223-37. doi: 10.1002/jcb.20045. J Cell Biochem. 2004. PMID: 15108350

8

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.

Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. Daud A, et al. Clin Cancer Res. 2005 Apr 15;11(8):3009-16. doi: 10.1158/1078-0432.CCR-04-1722. Clin Cancer Res. 2005. PMID: 15837755 Clinical Trial.

9

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: munster pn. Cancer Res. 2005 May 1;65(9):3815-22. doi: 10.1158/0008-5472.CAN-04-2478. Cancer Res. 2005. PMID: 15867379

10

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: munster pn. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. doi: 10.1158/1535-7163.MCT-05-0194. Mol Cancer Ther. 2005. PMID: 16373714

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

166 results

Search Page

Filters